Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Lymph nodes: where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.
November 11, 2020 ||
Elicio Announces Additions to Board of Directors
Elicio Therapeutics, a next generation immunotherapy company, has named Daphne Karydas, Chief Financial Officer at Syndax Pharmaceuticals and Carol Ashe, Chief Business Officer at the New York Genome Center, to its board of directors. » Read more
November 10, 2020 ||
Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting
Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity. » Read more
Orchestrating the immune system for precision immunity — Download this articleto see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.